DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application Main Article Content Srinivas Sidgiddi Usha Ranganathan Anirudh Gautam Keywords tazarotene, pharmacokinetic, skin Abstract Abstract Not Available Article Sidebar Poster PDF Published Oct 27, 2017 DOI https://doi.org/10.25251/skin.1.supp.45 Article Details How to Cite Sidgiddi, S., Ranganathan, U., & Gautam, A. (2017). DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application. SKIN The Journal of Cutaneous Medicine, 1(3.1), s46. https://doi.org/10.25251/skin.1.supp.45 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver Issue Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas Section Acne & Rosacea This work is licensed under a Creative Commons Attribution 4.0 International License. Authors transfer copyright to the publisher as part of the journal publishing agreement.All reprints are subject to the reprint policy.